Wall Street analysts expect that Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will report ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.17). Xeris Pharmaceuticals posted earnings per share of ($0.41) in the same quarter last year, which indicates a positive year over year growth rate of 46.3%. The company is expected to issue its next quarterly earnings results on Tuesday, March 8th.
On average, analysts expect that Xeris Pharmaceuticals will report full-year earnings of ($1.26) per share for the current year, with EPS estimates ranging from ($1.40) to ($1.17). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.57) to ($0.45). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings results on Tuesday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). Xeris Pharmaceuticals had a negative net margin of 267.90% and a negative return on equity of 382.91%. The business had revenue of $11.04 million for the quarter, compared to analysts’ expectations of $10.43 million. During the same period last year, the business earned ($0.35) earnings per share.
XERS stock opened at $2.22 on Wednesday. The company has a market capitalization of $147.62 million and a PE ratio of -1.47. The company’s fifty day moving average price is $2.30 and its 200-day moving average price is $2.67. The company has a debt-to-equity ratio of 4.40, a quick ratio of 2.95 and a current ratio of 3.34. Xeris Pharmaceuticals has a one year low of $1.77 and a one year high of $7.94.
In other news, insider Paul R. Edick purchased 20,000 shares of the business’s stock in a transaction on Monday, November 15th. The stock was purchased at an average price of $2.28 per share, with a total value of $45,600.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.01% of the company’s stock.
A number of institutional investors have recently modified their holdings of XERS. FMR LLC grew its holdings in shares of Xeris Pharmaceuticals by 29.9% in the 1st quarter. FMR LLC now owns 2,963,018 shares of the company’s stock valued at $29,749,000 after acquiring an additional 682,050 shares in the last quarter. Millennium Management LLC grew its holdings in Xeris Pharmaceuticals by 165.2% during the second quarter. Millennium Management LLC now owns 454,537 shares of the company’s stock worth $1,850,000 after purchasing an additional 283,142 shares during the period. SG Americas Securities LLC bought a new position in Xeris Pharmaceuticals during the second quarter worth about $994,000. Vanguard Group Inc. lifted its position in Xeris Pharmaceuticals by 8.5% during the second quarter. Vanguard Group Inc. now owns 2,980,367 shares of the company’s stock worth $12,131,000 after acquiring an additional 234,322 shares during the last quarter. Finally, Deltec Asset Management LLC lifted its position in Xeris Pharmaceuticals by 67.2% during the third quarter. Deltec Asset Management LLC now owns 460,500 shares of the company’s stock worth $1,128,000 after acquiring an additional 185,000 shares during the last quarter. 26.37% of the stock is currently owned by institutional investors and hedge funds.
About Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc is a holding company. It offers a novel formulation technology to bring ready-to-use, liquid-stable injectable to patients to remove many associated treatment burdens. The company was founded on May 20, 2021 and is headquartered in Chicago, IL.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.